Skip to main content

Table 6 Annual transitions (stated as percentages)

From: Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US

Transition

Baseline

Range

Reference

Chronic Hepatitis C

   

 to Compensated Cirrhosis

7.30 %

1.0 %-23.2 %

[6, 25]

Compensated Cirrhosis

   

 to Decompensated Cirrhosis

3.90 %

2.0 %-8.3 %

[22, 25, 29]

 to HCC

3.70 %

1.0 %-4.4 %

[25, 30, 31]

Decompensated Cirrhosis

   

 to HCC

3.70 %

1.0 %-4.4 %

[25, 29, 30]

 to Liver Transplant

3 %

1.0 %-6.2 %

[22, 25]

 to Liver-induced Death

12.90 %

6.5 %-19.3 %

[15, 22, 24, 29]

HCC

   

 to Liver Transplant

3 %

1.0-6.2 %

[22, 25]

 to Liver-induced Death

42.70 %

33 %-86 %

[25, 29]

Liver Transplant

   

 to Liver-induced Death, first year

13.70 %

6 %-42 %

[25, 32]

 to Liver-induced Death, successive year

5.20 %

2.4 %-11 %

[25, 32]